These documents matter because they prove there is no legal barrier to the health minister directing the PBAC in how it applies the cost-effectiveness framework and that, in fact, this exercise of power is critical to achieving real change. …
The minister exercised their power, the PBAC welcomed it, and the system changed
January 9, 2023 Latest NewsBioPharmaComment
Latest Video
New Stories
-
The 'Dispatched' Week in Review Podcast - 26 June
June 26, 2026 - - Podcast -
Arrotex and CStone partner to bring new anti PD-L1 therapy to Australia and New Zealand
June 26, 2026 - - Latest News -
Australia's next industry agreements might put more biologics squarely in the frame
June 26, 2026 - - Latest News -
Guild says pharmacy a solution as AMA flags ambulance ramping crisis
June 26, 2026 - - Latest News -
LENZ and Arrotex partner to bring once daily presbyopia treatment to Australia and New Zealand
June 25, 2026 - - Latest News -
Key report findings - 'Cost of Inaction - Australian voices on equitable access to diabetes technology'
June 25, 2026 - - BioPharma -
New report highlights the risk of inaction on diabetes technology
June 25, 2026 - - Latest News